3
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
23
Observational
5
Expanded_access
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma of Lung
1
Interventions
Afatinib
3
ceritinib
2
Gefitinib
2
zipalertinib
1
zenocutuzumab
1
ulixertinib
1
trilaciclib
1
telisotuzumab vedotin
1
tazemetostat
1
taletrectinib
1
sotorasib
1
selpercatinib
1
rovalpituzumab tesirine
1
rociletinib
1
pralsetinib
1
pegilodecakin
1
patritumab deruxtecan
1
osimertinib
1
mobocertinib
1
lorlatinib
1
lazertinib
1
epigallocatechin gallate
1
ensartinib
1
dabrafenib
1
cemiplimab
1
capmatinib
1
brigatinib
1
belagenpumatucel L
1
balstilimab
1
amivantamab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Expanded_access
×
capmatinib
×
Thoracic
×
Clear all
NCT04741789
2026-03-16
Managed Access Programs for INC280, Capmatinib
Novartis
No longer available